Axsome Therapeutics (NASDAQ:AXSM) COO Mark Jacobson Sells 35,378 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark Jacobson sold 35,378 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $161.88, for a total transaction of $5,726,990.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Axsome Therapeutics Price Performance

NASDAQ:AXSM traded up $0.70 during mid-day trading on Friday, reaching $163.89. The stock had a trading volume of 613,754 shares, compared to its average volume of 697,883. The stock has a 50-day simple moving average of $175.55 and a two-hundred day simple moving average of $145.65. The stock has a market capitalization of $8.38 billion, a PE ratio of -44.41, a P/E/G ratio of 34.93 and a beta of 0.40. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.50. Axsome Therapeutics, Inc. has a 12 month low of $86.99 and a 12 month high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.14. The firm had revenue of $196.00 million during the quarter, compared to analysts’ expectations of $191.33 million. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.Axsome Therapeutics’s revenue was up 65.0% compared to the same quarter last year. On average, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP acquired a new position in Axsome Therapeutics in the fourth quarter valued at approximately $2,366,000. Virtu Financial LLC acquired a new stake in Axsome Therapeutics in the fourth quarter worth $2,844,000. Invesco Ltd. grew its holdings in Axsome Therapeutics by 28.6% in the fourth quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock worth $232,591,000 after purchasing an additional 282,937 shares during the period. Strive Financial Group LLC bought a new stake in Axsome Therapeutics in the fourth quarter valued at $62,000. Finally, Ameriflex Group Inc. acquired a new position in shares of Axsome Therapeutics during the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on AXSM shares. Morgan Stanley set a $207.00 price target on shares of Axsome Therapeutics in a report on Tuesday. Robert W. Baird set a $209.00 price target on Axsome Therapeutics in a report on Tuesday, January 13th. TD Cowen reaffirmed a “buy” rating on shares of Axsome Therapeutics in a research note on Monday. Guggenheim lifted their price target on shares of Axsome Therapeutics from $205.00 to $220.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Jefferies Financial Group set a $215.00 target price on Axsome Therapeutics in a report on Monday. Seventeen investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $216.12.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.